(1/5) Encouraging pre-print out of Korea (though some important limitations to note): a collection of already FDA-approved drugs show strong efficacy against #Covid_19 in cell cultures. They highlighted two they found particularly promising: #niclosamide and #ciclesonide.

https://twitter.com/biorxiv_micrbio/status/1241218145957937158

(2/5) ciclesonide PROS: 1. already been used on patients in Japan www3.nhk.or.jp/nhkworld/en/ne… 2. Appears specific to coronoavirus biorxiv.org/content/10.110… 3. Can be administered by inhalation

1/13 While #COVID19 warrants our attention and swift, concerted action, we cannot forget about the existing high global burden diseases like #tuberculosis. 2/13 In ”Exact mapping of Illumina blind spots in the Mycobacterium tuberculosis genome reveals platform-wide and workflow-specific biases” preview.tinyurl.com/vyhckyc, @crobinhold1 @Valafarlab & I provide a roadmap for navigating #Illumina coverage bias when #sequencing Mtb #genomes